By Fineline Cube 
Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing approval in January 2025. The therapy is indicated for patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract, following the failure of hormone therapy.
Pricing and Cost Comparison
The mesenchymal stem cells (MSCs) therapy, the first of its kind in China, is priced at RMB 19,800 (USD 2,757) per dose. A full course of treatment requires 8 doses, totaling RMB 158,400 (USD 22,058). This represents just 1/70th the cost of similar products in the US.
Significance
Ruibosheng offers a new treatment option for patients with aGVHD, providing a more affordable alternative to existing therapies. Its introduction marks a significant advancement in the treatment landscape for this condition in China.-Fineline Info & Tech